Disulfiram with or without metformin inhibits oesophageal squamous cell carcinoma in vivo. (28th March 2018)
- Record Type:
- Journal Article
- Title:
- Disulfiram with or without metformin inhibits oesophageal squamous cell carcinoma in vivo. (28th March 2018)
- Main Title:
- Disulfiram with or without metformin inhibits oesophageal squamous cell carcinoma in vivo
- Authors:
- Jivan, Rupal
Peres, Jade
Damelin, Leonard Howard
Wadee, Reubina
Veale, Robin Bruce
Prince, Sharon
Mavri-Damelin, Demetra - Abstract:
- Abstract: Oesophageal squamous cell carcinoma (OSCC) is highly prevalent in developing countries but there has been little recent progress into efficacious yet affordable treatment strategies. Drug repurposing is one attractive approach for cancer therapy. Disulfiram (DSF), used to treat alcoholism, inhibits cancer growth and we previously found that DSF perturbs protein degradation/turnover pathways in vitro . This was enhanced by combining DSF with the anti-diabetic drug metformin (Met). Here, we investigated DSF with/without Met, against OSCC in vivo . Nude mice injected subcutaneously with the human OSCC cell line WHCO1, were treated with 30 mg/kg or 50 mg/kg DSF three times per week and with/without Met, for 21 days. DSF and DSF/Met-treated animals had significantly smaller tumours compared to untreated, vehicle and positive control cisplatin-treated groups. This effect for DSF was independent of copper, with no significant accumulation of copper in tumours, together with maintained proteasome activity. However, increases in total ubiquitinated proteins, LC3B-II, LAMP1 and p62 in DSF and DSF/Met groups, indicate that autophagy is inhibited. These findings show that DSF and DSF/Met significantly impede OSCC tumour growth in vivo and offer prospective alternative chemotherapy approaches for OSCC. Highlights: OSCC is highly prevalent in developing, resource-limited countries. Disulfiram is an attractive cancer chemotherapy candidate for drug repurposing. DSF with orAbstract: Oesophageal squamous cell carcinoma (OSCC) is highly prevalent in developing countries but there has been little recent progress into efficacious yet affordable treatment strategies. Drug repurposing is one attractive approach for cancer therapy. Disulfiram (DSF), used to treat alcoholism, inhibits cancer growth and we previously found that DSF perturbs protein degradation/turnover pathways in vitro . This was enhanced by combining DSF with the anti-diabetic drug metformin (Met). Here, we investigated DSF with/without Met, against OSCC in vivo . Nude mice injected subcutaneously with the human OSCC cell line WHCO1, were treated with 30 mg/kg or 50 mg/kg DSF three times per week and with/without Met, for 21 days. DSF and DSF/Met-treated animals had significantly smaller tumours compared to untreated, vehicle and positive control cisplatin-treated groups. This effect for DSF was independent of copper, with no significant accumulation of copper in tumours, together with maintained proteasome activity. However, increases in total ubiquitinated proteins, LC3B-II, LAMP1 and p62 in DSF and DSF/Met groups, indicate that autophagy is inhibited. These findings show that DSF and DSF/Met significantly impede OSCC tumour growth in vivo and offer prospective alternative chemotherapy approaches for OSCC. Highlights: OSCC is highly prevalent in developing, resource-limited countries. Disulfiram is an attractive cancer chemotherapy candidate for drug repurposing. DSF with or without metformin reduces OSCC tumour growth in vivo. … (more)
- Is Part Of:
- Cancer letters. Volume 417(2018)
- Journal:
- Cancer letters
- Issue:
- Volume 417(2018)
- Issue Display:
- Volume 417, Issue 2018 (2018)
- Year:
- 2018
- Volume:
- 417
- Issue:
- 2018
- Issue Sort Value:
- 2018-0417-2018-0000
- Page Start:
- 1
- Page End:
- 10
- Publication Date:
- 2018-03-28
- Subjects:
- Disulfiram -- Autophagy -- Protein degradation -- Metformin -- Oesophageal squamous cell carcinoma -- Drug repurposing
OSCC oesophageal squamous cell carcinoma -- DSF disulfiram -- Met metformin -- LC3B microtubule-associated light chain protein B -- 5-FU 5-fluorouracil -- DDTC-Me diethyldithiocarbamic acid-methyl ester -- DDC diethyldithiocarbamate -- DMEM/F12 Dulbecco's Modified Eagle Medium/Hams F12 -- s.c. subcutaneously -- DMSO dimethyl sulfoxide -- PEG40 polyethylene glycol 40 -- ANOVA analysis of variance -- H&E haematoxylin and eosin -- FFPE formalin fixed paraffin embedded -- FITC fluorescein isothiocyanate -- DAPI 4′, 6-diamidine-2′-phenylindole dihydrochloride -- PMSF phenylmethylsulfonyl fluoride -- Suc-LLVY-AMC N-succinyl-Leucine-Leucine-Valine-Tyrosine-amido-4-methylcoumarin -- DTT dithiothreitol -- ICP-MS inductively coupled plasma-mass spectrometry -- HPF high power fields -- LVI lymphovascular invasion -- PNI perineural infiltration -- IFB immunofluorescence buffer
Cancer -- Periodicals
Neoplasms -- Periodicals
Cancer -- Périodiques
Electronic journals
616.994 - Journal URLs:
- http://www.sciencedirect.com/science/journal/03043835/ ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.canlet.2017.12.026 ↗
- Languages:
- English
- ISSNs:
- 0304-3835
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3046.485000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 5737.xml